Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality by Garan, A. Reshad et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Cardiology Articles Cardiology/Cardiovascular Research 
11-1-2020 
Complete Hemodynamic Profiling With Pulmonary Artery 
Catheters in Cardiogenic Shock Is Associated With Lower In-
Hospital Mortality 
A. Reshad Garan 
Manreet Kanwar 
Katherine L. Thayer 
Evan Whitehead 
Elric Zweck 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles 
Recommended Citation 
Garan AR, Kanwar M, Thayer KL, Whitehead E, Zweck E, Hernandez-Montfort J, Mahr C, Haywood JL, 
Harwani NM, Wencker D, Sinha SS, Vorovich E, Abraham J, O'Neill W, Burkhoff D, and Kapur NK. Complete 
Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower 
In-Hospital Mortality. JACC Heart Fail 2020; 8(11):903-913. 
This Article is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford 
Health System Scholarly Commons. It has been accepted for inclusion in Cardiology Articles by an authorized 
administrator of Henry Ford Health System Scholarly Commons. 
Authors 
A. Reshad Garan, Manreet Kanwar, Katherine L. Thayer, Evan Whitehead, Elric Zweck, Jaime Hernandez-
Montfort, Claudius Mahr, Jillian L. Haywood, Neil M. Harwani, Detlef Wencker, Shashank S. Sinha, Esther 
Vorovich, Jacob Abraham, William O'Neill, Daniel Burkhoff, and Navin K. Kapur 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
cardiology_articles/664 
Complete Hemodynamic Profiling With
Pulmonary Artery Catheters in
Cardiogenic Shock Is Associated With
Lower In-Hospital Mortality
A. Reshad Garan, MD, MS,a,* Manreet Kanwar, MD,b,* Katherine L. Thayer, MPH,c Evan Whitehead, MD,d
Elric Zweck, MSC,c,e Jaime Hernandez-Montfort, MD, MPH,f Claudius Mahr, DO,g Jillian L. Haywood, MS,c
Neil M. Harwani, MS,c Detlef Wencker, MD,h Shashank S. Sinha, MD, MSC,i Esther Vorovich, MD,j
Jacob Abraham, MD,k William O’Neill, MD,l Daniel Burkhoff, MD, PHD,m Navin K. Kapur, MDc
ABSTRACT
OBJECTIVES The purpose of this study was to investigate the association between obtaining hemodynamic data from
early pulmonary artery catheter (PAC) placement and outcomes in cardiogenic shock (CS).
BACKGROUND Although PACs are used to guide CS management decisions, evidence supporting their optimal use in
CS is lacking.
METHODS The Cardiogenic Shock Working Group (CSWG) collected retrospective data in CS patients from 8 tertiary
care institutions from 2016 to 2019. Patients were divided by Society for Cardiovascular Angiography and Interventions
(SCAI) stages and outcomes analyzed by the PAC-use group (no PAC data, incomplete PAC data, complete PAC data) prior
to initiating mechanical circulatory support (MCS).
RESULTS Of 1,414 patients with CS analyzed, 1,025 (72.5%) were male, and 494 (34.9%) presented with myocardial
infarction; 758 (53.6%) were in SCAI Stage D shock, and 263 (18.6%) were in Stage C shock. Temporary MCS devices were
used in 1,190 (84%) of those in advanced CS stages. PAC data were not obtained in 216 patients (18%) prior to MCS,
whereas 598 patients (42%) had complete hemodynamic data. Mortality differed significantly between PAC-use groups
within the overall cohort (p < 0.001), and each SCAI Stage subcohort (Stage C: p ¼ 0.03; Stage D: p ¼ 0.05; Stage E:
p ¼ 0.02). The complete PAC assessment group had the lowest in-hospital mortality than the other groups across all
SCAI stages. Having no PAC assessment was associated with higher in-hospital mortality than complete PAC assessment
in the overall cohort (adjusted odds ratio: 1.57; 95% confidence interval: 1.06 to 2.33).
CONCLUSIONS The CSWG is a large multicenter registry representing real-world patients with CS in the contemporary
MCS era. Use of complete PAC-derived hemodynamic data prior to MCS initiation is associated with improved survival
from CS. (J Am Coll Cardiol HF 2020;8:903–13) © 2020 by the American College of Cardiology Foundation.
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C ardiogenic shock (CS) is a conditionof low cardiac output (CO) withpersistent hypotension, hypoperfu-
sion, and life-threatening multiorgan failure
attributable to impaired ventricular function
(left or right, or both) (1–2). Pulmonary artery
catheters (PACs) directly measure pulmonary
and cardiac pressures and oxygen saturation
and are used to calculate an array of hemody-
namic parameters including CO and vascular
resistances. Such monitoring facilitates
triage and management of patients present-
ing with acute hemodynamic decompensa-
tion. Specifically, PACs allow operators to
assess the relative contributions of right and
left ventricular failure to guide medical ther-
apy with vasoactive medications, inotropes,
and mechanical circulatory support (MCS)
device(s) for CS (3). However, no definitive
randomized controlled trial has tested the
utility of PACs for CS.
Retrospective and prospective studies have
shown no benefit from PAC-guided treatment in
patients with decompensated heart failure (DHF)
(4–6). However, patients with CS are conventionally
excluded from clinical trials assessing the use of
PACs. Recently, a 5-stage CS classification scheme
was proposed by a multidisciplinary group of ex-
perts from the Society for Cardiovascular Angiog-
raphy and Interventions (SCAI) to differentiate
among patient subsets based on severity (7). Recent
widespread availability of short-term percutaneous
MCS devices for CS has led to proposed manage-
ment algorithms guided by PAC-derived invasive
hemodynamic data (8,9). Similarly, studies using
hemodynamically-guided decision making have
shown improved outcomes with the use of PAC in
CS (3,10,11). A recent white paper dealing with PAC
use in CS recommended that PACs be used in all
patients undergoing MCS to monitor effectiveness,
optimize device settings, assess the need for esca-
lation, and guide timing and rate of weaning (3).
However, no studies have explored whether com-
plete hemodynamic profiling using PAC is associ-
ated with clinical outcomes in CS. This study sought
to investigate the association between the use of
PAC prior to initiation of MCS and clinical outcomes
in CS by using data from the Cardiogenic Shock
Working Group (CSWG) registry. Hypothetically, the
timely use of complete PAC measurements would
be associated with outcomes in patients with
advanced shock, as defined by the SCAI CS staging
system.
METHODS
DATA SOURCE. The CSWG is an academic research
consortium with a national registry begun in 2016. A
group of 16 clinical sites across the United States
contributed CS patient data (Supplemental Table 1).
Those sites included community and university hos-
pitals with registry inclusion dependent on a mini-
mum of 100 patients with CS per year. For this
analysis, patients with CS at the first 8 sites contrib-
uting registry data between 2016 and 2019 were
included, regardless of CS cause. The registry details
a standardized set of data elements which were pre-
defined by principal investigators and collected
retrospectively. Elements included patient, proce-
dural, and hospital characteristics. Patient de-
mographics, laboratory, and hemodynamic data were
collected at a single time point as close to admission
as possible, prior to short-term MCS (i.e., use of an
intra-aortic balloon pump [IABP], the Impella
(Abiomed, Danvers, Massachusetts), venoarterial ex-
tra corporeal membrane oxygenation [VA-ECMO], or
extracorporeal centrifugal flow pumps) initiation. CS
diagnosis was physician-adjudicated at each site and
defined as follows: a sustained episode of systolic
blood pressure <90 mm Hg for at least 30 mins or use
of vasoactive agents and/or a cardiac index value
of <2.2 l/min/m2 determined to be secondary to car-
diac dysfunction, in the absence of hypovolemia; or
use of an MCS device for clinically suspected CS.
Treatments for CS were left to the discretion of the
clinicians at each center and were not guided by a
prescribed algorithm. Both the use of vasopressors/
inotropes and of MCS at any time throughout a pa-
tient’s hospitalization was used to assign SCAI stages
in the study cohort as described in an earlier report
from this registry (12). Quality assurance was ach-
ieved through adjudication at each site by the
respective clinical coordinators and principal inves-
tigator. Values were centrally audited and screened
by the CSWG research team for any discrepancies or
major outliers and resolved with the submitting site.
This study was approved by the Tufts Health Sciences
Institutional Review Board, and all sites contributing
data (Supplemental Table 1) received approval to
include data in this registry from their respective
Institutional Review Board.
STUDY POPULATION. Between 2016 and 2019, data
from 1,565 patients with CS were collected. The cau-
se(s) of CS were reported by each site as acute
myocardial infarction (AMI), acute DHF, or other. AMI
SEE PAGE 914
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AMI = acute myocardial
infarction
CO = cardiac output
CS = cardiogenic shock




IABP = intra-aortic balloon
pump
MCS = mechanical circulatory
support
PAC = pulmonary artery
catheter
PCWP = pulmonary capillary
wedge pressure
RAP = right atrial pressure
SCAI = Society for
Cardiovascular Angiography
and Interventions
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was defined as any primary diagnosis of either non-
ST-segment elevation or ST-segment elevation AMI.
Acute DHF was defined as any primary diagnosis of
acute or chronic HF not otherwise related to AMI.
Other causes included postcardiotomy, myocarditis,
or CS not otherwise specified. Patients younger than
18 years of age (n ¼ 10.06%) and those with unknown
mortality status at hospital discharge (n ¼ 150; 9.6%)
were excluded, leaving a study population of 1,414
patients with CS from 8 hospitals for analysis. Then a
recently published SCAI CS staging system was
applied to stratify this cohort by SCAI stage, as pre-
viously described, allowing evaluation of PAC utility
across the spectrum of CS severity (12).
According to the SCAI stages, clinical deterioration
based on persistent hypotension and hypoperfusion
is the main determinant of the SCAI Stage and is
associated with a need for intensification of treat-
ment (7). Therefore, treatment escalation for CS was
used as a proxy for persistent hypotension and
hypoperfusion to retrospectively define maximum
deterioration as hemometabolic parameters were
only assessed at admission. A CSWG-adapted defini-
tion of SCAI stages was applied to this study cohort
based on total use of vasopressors, inotropes, and
MCS across a patient’s hospital course (Figure 1) (12).
SCAI Stage A patients are those at risk for CS and
therefore were not captured in this study population.
Stage B patients are those exhibiting early symptoms
not including hypoperfusion and therefore did not
require pharmacological or MCS. Stage C patients
include those with hypotension and hypoperfusion
requiring intervention beyond volume resuscitation
including those requiring either 1 vasopressor/ino-
trope or 1 MCS device. Stage D patients are those
whose conditions deteriorate despite initial
intervention, defined in this dataset by the need for
multiple drugs or MCS devices. Finally, Stage E pa-
tients are those who deteriorate further and require
maximal support, defined in this dataset as requiring
at least 2 MCS devices and 2 drugs during their hos-
pitalization. Patients requiring cardiopulmonary
resuscitation on admission were included in Stage E.
CLASSIFICATION OF PAC USAGE. Patients were
divided into 3 categories: those with a complete PAC
assessment, those with an incomplete assessment,
and those who did not receive a PAC catheter prior to
MCS initiation. PAC usage was defined in the popu-
lation by the presence of invasive hemodynamic pa-
rameters including right atrial pressure (RAP),
pulmonary artery systolic pressure, pulmonary artery
diastolic pressure (PADP), pulmonary capillary wedge
pressure (PCWP), pulmonary artery (PA) oxygen
saturation, and CO. Complete hemodynamic profiling
with PAC required documentation of 5 measure-
ments: RAP, pulmonary artery systolic pressure,
PADP, PCWP, and PA saturation. Measured values
were chosen instead of derived values to ensure ac-
curacy of groupings (e.g., although there are other
methods for estimating CO, there is no way to esti-
mate PA saturation). Calculated hemodynamic pa-
rameters derived from the above-mentioned
measurements (cardiac index, mean pulmonary ar-
tery pressure, systemic vascular resistance, cardiac
power output, pulmonary artery pulsatility index,
and so forth) were noted but not essential for desig-
nations as a complete profile. If any of these 5 he-
modynamic values were not reported (e.g., only RAP
or oxygen saturation documented from a central
venous catheter, or pulmonary artery pressure
documented in the absence of PCWP and so forth),
FIGURE 1 Stages of Cardiogenic Shock
Adapted from Baran et al. (7). CSWG ¼ Cardiogenic Shock Working Group; SCAI ¼ Society for Cardiovascular Angiography and Intervention.
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TABLE 1 Baseline Characteristics of Cardiogenic Shock Patients Across 3 Subgroups
All (N [ 1,414)
PAC Usage
p ValueNone (n ¼ 260) Incomplete Assessment (n ¼ 556) Complete Assessment (n ¼ 598)
Males 1,025 (72.5) 196 (73.4) 413 (75.2) 416 (69.6) 0.085
Race <0.001
White 647 (45.8) 138 (51.7) 158 (28.8) 351 (58.7)
Hispanic/Latino 31 (2.2) 11 (4.1) 10 (1.8) 10 (1.7)
African-American 28 (2.0) 10 (3.7) 5 (0.9) 13 (2.2)
Asian 31 (2.2) 13 (4.9) 10 (1.8) 8 (1.3)
Other 82 (5.8) 5 (1.9) 6 (1.1) 71 (11.9)
Medical history
Hypertension 681 (48.2) 145 (54.3) 262 (47.7) 274 (45.8) <0.001
Diabetes mellitus 489 (34.6) 79 (29.6) 212 (38.6) 198 (33.1) 0.030
Atrial fibrillation 296 (20.9) 20 (7.5) 90 (16.4) 186 (31.1) <0.001
Prior MI 374 (26.4) 54 (20.2) 168 (30.6) 152 (25.4) <0.001
Prior HF 768 (54.3) 87 (32.6) 286 (52.1) 395 (66.1) <0.001
Chronic kidney disease 323 (22.8) 43 (16.1) 110 (20.0) 170 (28.4) 0.004
Peripheral vascular disease 60 (4.2) 13 (4.9) 13 (2.4) 34 (5.7) 0.722
COPD 101 (7.1) 13 (4.9) 32 (5.8) 56 (9.4) 0.108
Stroke/TIA 159 (11.2) 20 (7.5) 54 (9.8) 85 (14.2) 0.116
Valvular disease 214 (15.1) 20 (7.5) 56 (10.2) 138 (23.1) <0.001
PCI 293 (20.7) 63 (23.6) 118 (21.5) 112 (18.7) <0.001
CABG 114 (8.1) 18 (6.7) 46 (8.4) 50 (8.4) 0.056
Ventricular tachycardia 216 (15.3) 22 (8.2) 54 (9.8) 140 (23.4) <0.001
ICD 329 (23.3) 25 (9.4) 84 (15.3) 220 (36.8) <0.001
CRT 97 (6.9) 4 (1.5) 37 (6.7) 56 (9.4) <0.001
Low institutional PAC placement 313 (22.14) 140 (52.43) 112 (20.40) 61 (10.20) <0.001
Demographics
Age 1,412 (59.91  14.78) 265 (62.41  15.38) 549 (60.28  13.32) 598 (58.47  15.60) 0.011
Weight, kg 1,138 (85.25  22.62) 219 (87.37  21.37) 323 (84.63  25.53) 596 (84.82  21.35) 0.305
Metabolic panel
AST 788 (459.41  1,492.57) 115 (329.06  1,044.31) 236 (574.09  1,413.83) 437 (431.78  1,626.74) 0.299
BUN 1,026 (32.38  20.47) 165 (26.32  16.46) 321 (32.02  20.64) 540 (34.44  21.12) <0.001
Lactate 676 (4.37  4.21) 99 (6.09  4.82) 328 (3.97  3.95) 249 (4.21  4.14) <0.001
Bicarbonate 836 (22.12  5.45) 119 (19.97  5.20) 245 (20.74  5.16) 472 (23.38  5.31) <0.001
Serum creatinine 1,295 (1.76  1.14) 182 (1.7  1.29) 520 (1.86  1.16) 593 (1.70  1.07) 0.041
pH 576 (7.31  0.15) 110 (7.25  0.17) 255 (7.32  0.14) 211 (7.32  0.13) <0.001
Echocardiography
Admission EF 771 (24.94  15.53) 112 (31.79  17.27) 348 (23.74  15.14) 311 (23.81  14.68) <0.001
LVEDD 996 (5.89  1.37) 108 (5.01  1.05) 397 (6.01  1.4) 491 (5.99  1.35) <0.001
Heart rate 1,248 (92.02  22.72) 195 (89.99  27.5) 470 (94.8  23.07) 583 (90.45  20.38) 0.003
SBP 1,245 (98.17  20.02) 192 (101.26  26.3) 472 (97.52  18.36) 581 (97.68  18.82) 0.07
DBP 1,241 (61.98  13.95) 191 (61.88  15.98) 470 (61.73  13.94) 580 (62.22  13.25) 0.85
Hemodynamics
RAP 1,030 (14.2  6.95) - 432 (14.87  7.12) 598 (13.71  6.79) 0.008
PCWP 848 (24.5  8.9) - 250 (26.12  9.21) 598 (23.82  8.68) <0.001
MAP 1,117 (74.26  13.95) - 527 (74.28  14.46) 590 (74.25  13.5) 0.97
mPAP 1,074 (32.73  9.86) - 476 (33.16  10.18) 598 (32.39  9.59) 0.20
PASP 1,080 (47.67  15.1) - 482 (48.5  15.76) 598 (47.00  14.53) 0.10
PADP 1,074 (25.3  8.25) - 476 (25.57  8.48) 598 (25.09  8.07) 0.34
PA sat 755 (52.02  13.55) - 157 (53.48  17.25) 598 (51.64  12.39) 0.13
CPO 988 (0.63  0.41) – 432 (0.63  0.42) 556 (0.63  0.41) 0.98
Cardiac index 1,057 (1.86  0.59) - 474 (1.85  0.63) 583 (1.86  0.56) 0.78
Cardiac output 1,050 (3.84  2.43) - 464 (3.86  2.65) 586 (3.83  2.23) 0.83
Values are n (%) or n (mean  SD).
AST ¼ aspartate aminotransferase; BUN ¼ blood urea nitrogen; CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; CPO ¼ cardiac power output; CRT ¼ cardiac
resynchronization therapy; DBP ¼ diastolic blood pressure; EF ¼ ejection fraction; HF ¼ heart failure; ICD ¼ implantable cardioverter-defibrillator; LVEDD ¼ left ventricular end diastolic diameter; MAP ¼
mean arterial pressure; MI ¼ myocardial infarction; mPAP ¼ mean pulmonary artery pressure; PA sat ¼ pulmonary artery oxygen saturation; PAC ¼ pulmonary artery catheter; PADP ¼ pulmonary artery
diastolic pressure; PASP ¼ pulmonary artery systolic pressure; PCI ¼ percutaneous coronary intervention; PCWP ¼ pulmonary capillary wedge pressure; RAP ¼ right atrial pressure; SBP ¼ systolic blood
pressure; TIA ¼ transient ischemic attack.
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the PAC assessment was considered incomplete. If a
PAC was placed after MCS initiation, the patient was
considered in the “no-PAC” category for the purpose
of this analysis. Institutions were defined as low-PAC
users if they were in the lowest tertile of PAC use
among the contributing centers, and this variable was
used in a multivariate model to control for variability
in center practice.
HEMODYNAMIC ASSESSMENT. To assess the impor-
tance of hemodynamic assessment on clinical out-
comes, the association between in-hospital mortality
and hemodynamic values obtained from PACs was
analyzed. Additional vital sign parameters (blood
pressure and heart rate) were also included. Hemo-
dynamic parameters were analyzed as categorical
variables split into quartiles within the overall study
cohort and in subcohorts based on CS cause (AMI-CS,
acute DHF-CS).
STATISTICAL ANALYSIS. Descriptive statistics were
analyzed among the 3 PAC subgroups to determine
differences in baseline characteristics. Categorical
variables were reported as frequencies and percent-
ages and compared using Pearson chi-squared tests.
Continuous variables were reported as mean  SD
and compared using independent t-tests. Differences
in mortality among groups were assessed using chi-
squared tests among the entire study cohort and
among subcohorts of varying CS severity, as defined
by previously validated maximum SCAI stages
reached across hospitalization. The association be-
tween PAC use and mortality was further analyzed in
a univariate logistic regression model and then
adjusted for other significant univariate predictors of
mortality including use of PAC at the study site,
comorbidities (hypertension, diabetes mellitus, ven-
tricular tachycardia, and implantable cardioverter-
defibrillator); and cause of shock and age in a multi-
variate model. These models were run in the overall
cohort as well as within each SCAI stage. Results from
logistic regression models were reported as odds ra-
tios (ORs) with 95% confidence intervals (CIs) Addi-
tionally, the frequency of in-hospital mortality was
compared across quartiles of each hemodynamic
parameter in the AMI-CS and acute DHF-CS cohorts
using the Pearson chi-squared test. An alpha level of
0.05 was used to determine significance for all sta-
tistical analyses.
RESULTS
Data from 1,414 patients at 8 clinical sites were
analyzed. Baseline characteristics are summarized in
Table 1. Of the study cohort, 1,025 patients (72.5%)
were male, and 712 (50.4%) presented with acute
DHF-CS. CS was treated with vasoactive and/or
pressor agents in 1,043 patients (73.8%). MCS devices
included IABPs in 770 (54.5%), an Impella device in
410 (29%), and ECMO in 333 patients (23.6%). A
number of patients (n ¼ 99; 7.0%) received multiple
MCS devices during their hospitalization. The major-
ity of patients (n ¼ 758, 53.6%) were in SCAI Stage D,
with 263 (18.6%) in Stage C and 212 (15%) in Stage E
shock. A total of 260 patients (18%) had no docu-
mented use of PAC prior to MCS, whereas 598 (42%)
had a complete set of hemodynamic data recorded. Of
those with an incomplete assessment (40%), PADP
and PCWP were most likely to be missing, followed by
PA saturation and RAP (Table 2).
Patients with acute DHF-CS were more likely to
have a complete PAC assessment than those with
AMI-CS (52.8% vs. 32.2%, respectively; p < 0.001)
(Table 3). Patients with CS not receiving MCS (n ¼ 224)
were more likely to have a complete PAC assessment
(79.9%); those with a complete assessment were more
likely to not escalate past SCAI Stage B (0.4% vs. 0.4%
vs. 7.2%, respectively; p < 0.001). Those treated with
ECMO (n ¼ 333) had a complete assessment
TABLE 2 Distribution of Hemodynamic Data Across Complete and Incomplete Groups
Hemodynamic
Parameters
Collected All (N ¼ 1,414)
Number of PAC Parameters Collected
0 (n ¼ 260) 1 (n ¼ 40) 2 (n ¼ 51) 3 (n ¼ 198) 4 (n ¼ 267) 5 (n ¼ 598)
PASP 1,080 (76.38) 0 (0.00) 1 (2.50) 19 (37.25) 195 (98.48) 267 (100.00) 598 (100.00)
PADP 1,074 (75.95) 0 (0.00) 0 (0.00) 17 (33.33) 192 (96.97) 267 (100.00) 598 (100.00)
PCWP 848 (59.97) 0 (0.00) 4 (10.00) 30 (58.82) 24 (12.12) 192 (71.91) 598 (100.00)
PA Sat 755 (53.39) 0 (0.00) 28 (70.00) 32 (62.75) 9 (4.55) 88 (32.96) 598 (100.00)
RAP 1,037 (73.34) 0 (0.00) 7 (17.50) 4 (7.84) 174 (87.88) 254 (95.13) 598 (100.00)
Values are n (%).
PA ¼ pulmonary artery; PA Sat ¼ pulmonary artery oxygen saturation; PAC ¼ pulmonary artery catheter; PADP ¼ pulmonary artery diastolic pressure; PASP ¼ pulmonary artery systolic pressure; PCWP ¼
pulmonary capillary wedge pressure; RAP ¼ right atrial pressure.
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performed prior to therapy in 23% of cases. Patients
who did not have invasive hemodynamics assessed
prior to treatment at the study site were more likely
to have a history of hypertension (54.3% vs. 47.7% vs.
45.8%, respectively; p < 0.001) whereas those with
incomplete assessment were more likely to be dia-
betic (29.6% vs. 38.6% vs. 33.1%, respectively;
p < 0.001).
PAC USAGE ASSOCIATION WITH MORTALITY. Crude
mortality among patients according to SCAI stages
were as follows: Stage B, 0%; Stage C, 10.65%; Stage
D, 32.98%; and Stage E, 55.19% (p < 0.001). Patients
whose CS had different causes experienced different
rates of mortality in aggregate (AMI-CS, 39.47%; acute
DHF-CS, 25.28%; and other 24.16%; p < 0.001). Mor-
tality differed significantly among PAC groups within
the overall cohort (p < 0.001) and each SCAI Stage
subcohort (Stage C; p ¼ 0.03; Stage D; p ¼ 0.05; Stage
E; p ¼ 0.02) (Central Illustration). The complete PAC
assessment group had the lowest in-hospital mortal-
ity compared to the other groups across all SCAI
stages. Similarly, in both the acute DHF-CS and the
AMI-CS cohorts, the complete PAC group had the
lowest mortality (p < 0.001 in acute DHF-CS, and
p ¼ 0.07 in the AMI-CS group). After adjustments
were made for comorbidities, cause of shock, and PAC
usage per site, as mentioned above, having no PAC
assessment was associated with significantly higher
odds of mortality than having full PAC assessment in
the overall cohort (adjusted OR: 1.57; 95% CI: 1.06 to
2.33) (Figure 2). Moreover, incomplete PAC assess-
ment was associated with higher odds of mortality
than complete PAC assessment in the overall cohort
(adjusted OR: 1.71; 95% CI: 1.29 to 2.25). There were
no significant differences between the odds of in-
hospital mortality in no-PAC and incomplete
PAC assessments.
HEMODYNAMIC PARAMETERS ASSOCIATED WITH
IN-HOSPITAL MORTALITY. Hemodynamic parame-
ters were available for analysis in 1,279 patients.
Differences in hemodynamic measurements among
the 3 groups are shown in Table 1, and the association
between individual parameters with in-hospital
mortality is shown in Figure 3. RAP and PCWP
differed between those in the incomplete and com-
plete PAC groups, but other hemodynamic parame-
ters did not. Mean arterial pressure (MAP) and RAP
differed significantly across quartiles in the overall,
AMI-CS, and acute DHF-CS cohorts. Their associations
appear to be linear, with decreased MAP and
increased RAP significantly associated with higher
mortality. Elevated heart rate was also associated
with higher mortality, although the trend does not
appear linear; PCWP, cardiac power output, and car-
diac index did not appear to impact mortality
consistently across the cohorts.
TABLE 3 Assessment of PAC Usage by SCAI Stages, Causes of CS, and Device Usage









Acute mechanical support treatment
No MCS 224 (15.8) 30 (13.4) 15 (6.7) 179 (79.9) <0.001
IABP 770 (54.5) 130 (16.9) 338 (43.9) 302 (39.2) <0.001
Impella 410 (29.0) 80 (19.5) 169 (41.2) 161 (39.3) 0.33
ECMO 333 (23.6) 95 (28.5) 161 (48.4) 77 (23.1) <0.001
Multiple MCS 308 (21.8) 62 (20.1) 124 (40.3) 122 (39.6) 0.55
Medical Therapy 1,043 (73.8) 109 (10.5) 445 (42.7) 489 (46.9) <0.001
Shock cause
MI 494 (34.9) 123 (24.9) 212 (42.9) 159 (32.2) <0.001
HF 712 (50.4) 57 (8.0) 286 (40.2) 369 (51.8) <0.001
Other 178 (12.6) 59 (33.2) 50 (28.1) 69 (38.8) <0.001
SCAI Stage
B 46 (3.3) 1 (2.2) 2 (4.4) 43 (93.5) <0.001
C 263 (18.6) 68 (25.9) 63 (24.0) 132 (50.2) <0.001
D 758 (53.6) 66 (8.7) 361 (47.6) 331 (43.7) <0.001
E 212 (15.0) 39 (18.4) 90 (42.5) 83 (39.2) <0.001
Values are n (%).
ECMO ¼ extra-corporeal membrane oxygenation; HF ¼ heart failure; IABP ¼ intra-aortic balloon pump; MCS ¼ mechanical circulatory support; MI ¼ myocardial infarction;
SCAI ¼ Society of Cardiovascular Angiography and Interventions.
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DISCUSSION
This study describes the association between clinical
outcomes and use of PAC in one of the largest
multicenter registries representing real-world pa-
tients with CS in the contemporary acute MCS era. It
was observed that CS patients with complete PAC
data obtained prior to MCS initiation had improved
survival compared to those who did not, even after
accounting for potentially confounding factors. This
difference was more pronounced in the sickest cohort
of patients (SCAI Stages D and E patients). Having an
incomplete hemodynamic dataset was equivalent to
having no PAC data with regard to in-hospital mor-
tality. These data represent one of the largest multi-
center “real-world” experiences with hemodynamic
assessment for CS across multiple tertiary care
centers.
The optimal use of hemodynamic monitoring with
PACs in hospitalized patients with HF remains
controversial. PACs became a ubiquitous feature of
intensive care unit management in the 1980s and
1990s until several large trials showed no benefit to
their use in broad populations of critically ill patients
(13). Their use further declined after the ESCAPE
(Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Effectiveness) trial
showed no benefit to routine use of PACs in decom-
pensated patients with HF, but notably that trial
excluded patients with CS (5). The 2013 American
College of Cardiology/American Heart Association HF
guidelines recommend the use of invasive hemody-
namic monitoring using a PAC to guide therapy in
patients with respiratory distress or evidence of
impaired perfusion in whom the adequacy or excess
of intracardiac filling pressures cannot be determined
from clinical assessment (Class I, Level of Evidence:
C) (14).
There have been major advances in acute HF
management recently and especially in CS with tem-
porary MCS therapy widely available (2). Early
recognition and triage of patients with CS using spe-
cific therapeutic algorithms is increasingly common,
including identification of the shock subtype and an
understanding of the expected impact of a devices on
parameters such as CO, PCWP, RAP, and MAP (3).
Knowledge of these parameters allows the practi-
tioner to choose the device or combination of devices
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PAC ¼ pulmonary artery catheter; SCAI ¼ Society of Cardiovascular Angiography and Interventions.
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that best match the patient’s needs. Additional ben-
efits from acquisition of complete PAC data include
early identification of patients with significant he-
modynamic compromise requiring immediate MCS, in
order to avoid irreversible end-organ dysfunction
resulting from treatment delays. Additionally, PAC
data facilitate early recognition of a biventricular
shock state which is often underappreciated and may
FIGURE 2 Adjusted Odds of Mortality Associated With Less Complete PAC Assessment
Odds ratios were adjusted for PAC use by institution, hypertension, cause of cardiogenic shock, diabetes, age, ventricular tachycardia, and
implantable cardioverter-defibrillator. PAC ¼ pulmonary artery catheter; SCAI ¼ Society of Cardiovascular Angiography and Interventions.
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require consideration of biventricular support (1).
Finally, the continuous feedback obtained from the
PAC facilitates optimization of volume status,
adjustment of vasoactive medications in a more tar-
geted fashion, and recognition of when patients can
be weaned from such devices. Single-center reports
have demonstrated that the use of PAC in patients
with CS has been associated with lower short- and
long-term mortality rates (15). Similarly, some regis-
tries have demonstrated an association between use
of PAC and improved outcomes, although these
datasets have lacked the granularity necessary to
further understand this association (10,11). Not sur-
prisingly, there is increasing focus on use of invasive
hemodynamic monitoring for the management of CS
(3).
The present analysis provides data from a large,
contemporary registry including patients supported
by multiple MCS device platforms to support the
timely use of PACs in reducing mortality in CS. It has
been previously established that patients with re-
fractory shock (SCAI shock Stage E) had >20-fold
higher crude in-hospital mortality than hemody-
namically stable patients without shock (SCAI shock
Stage A) (1). Not surprisingly, the present data pro-
mote the hypothesis that treatment decisions guided
by early and complete hemodynamic profiling in pa-
tients with greater degrees of hemodynamic
compromise lead to improved outcomes. This is likely
because PAC-derived hemodynamic data not only
confirm the severity of CS but also enable clinicians to
monitor responses to therapeutic interventions.
Much in the same way that “routine” use of PAC in
decompensated HF did not prove beneficial, the
benefit of obtaining PAC data in patients with less
severe shock was not as evident in the present data-
set. This is also reiterated in the American Heart As-
sociation scientific statement on management of CS,
which emphasizes PAC use in patients with moderate
to severe CS who are unresponsive to initial therapy
(2).
Patients with incomplete characterization of the
hemodynamic profile had worse outcomes than those
with a complete evaluation in the present analysis.
The authors speculate that this could be partly due to
a compromise in underestimating the degree of right
heart failure resulting in end-organ damage caused by
hypoperfusion and congestion. Hemodynamic moni-
toring is always meant to complement other markers
of end-organ perfusion in CS (2). However, estimation
of hemodynamics based on the physical examination
can be highly inaccurate, even for the experienced
clinician, with exaggerated rates of misrecognition of
the most high-risk patients (16). Using surrogates of a
complete hemodynamic assessment or obtaining
limited information from a PAC misses the
FIGURE 3 Frequency of Mortality by Hemodynamic Parameter Quartiles Assessed by Pac Stratified by Cause of Cardiogenic Shock
*p # 0.05; **p # 0.01; ***p # 0.001. NS ¼ not significant; PAC ¼ pulmonary artery catheter.
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opportunity to fully define the patient’s hemody-
namic profile to guide therapeutic decision making.
Various hemodynamic indices have been shown to
be prognostic indicators of outcomes in CS. In the
present analysis, MAP, RAP, and heart rate were
associated with mortality regardless of CS cause.
Other parameters demonstrated prognostic impor-
tance in subsets of the registry. For example, PCWP
correlated with mortality among patients with acute
DHF-CS but not those with AMI-CS. These findings
are consistent with those in other reports where
intracardiac filling pressures correlated with out-
comes in acute DHF patients (17). Interestingly, car-
diac power output, which was shown to be a powerful
prognostic measurement in AMI-CS, did not demon-
strate similar value in this dataset (18). This may be
due, in part, to the inclusion of multiple causes of
cardiogenic shock, where this parameter is not known
to have prognostic value. In addition, this difference
may be explained, in part, by widespread use of MCS
to improve this hemodynamic index in this registry
population. Indeed, measurements of indices such as
cardiac power outlet with PACs often informs de-
cisions regarding MCS application.
STUDY LIMITATIONS. The present data are retro-
spective in nature and include inherent limitations.
Patients in whom a PAC was placed after initiation of
MCS were scored as having no PAC data in the present
analysis. Furthermore, because registry data were
derived from documentation in electronic health re-
cords, “incomplete” PAC data may have included in-
stances where clinicians had complete PAC data at the
bedside but did not subsequently document a com-
plete set of hemodynamic values. It is important to
note that, although an association was observed be-
tween PAC use in CS and reduced mortality, one
cannot necessarily conclude causality. PAC-derived
hemodynamics are diagnostic data and do nothing
to improve the patient’s condition, unless those data
are interpreted accurately and are coupled with
expeditious use of a treatment strategy aimed at
improving outcomes. In addition, lack of PAC use may
be related to the acuity of the patient; often, the
severity of hemodynamic collapse can preclude the
need or opportunity for diagnostic studies until pa-
tients are stabilized. In the present data, those
requiring ECMO were least likely to have had a PAC
placed prior to initiation of therapy, although it is also
important to note that there was a relative under-
representation of SCAI Stage D and E patients in the
no-PAC group. Additionally, patients are often
transferred to tertiary care hospitals after initiation of
pressor/inotrope therapies or temporary MCS.
Centers may use “hybrid” methodologies to combine
minimally invasive and noninvasive methods to he-
modynamically monitor CS patients without a PAC.
However, real-world, multicenter registry reports
of more than 1,400 patients with CS help address the
pressing need for additional evidence of PAC use in
CS prior to initiation of MCS, which was emphasized
in a recently published white paper on the subject (3).
Future analyses will include prospectively collected
data with PAC and MCS timing captured in order to
examine how PAC data guide stepwise escalation of
MCS therapies and explore the impact of PAC use on
hospital costs and length of stay. Potentially impor-
tant variables were not included in this multivariate
model because they were missing in many cases (e.g.,
lactate concentrations) or missing disproportionately
in the study subsets (e.g., MAP), although we antici-
pate prospective data collection will dramatically
improve this limitation. Other key variables including
recent cardiac arrest and hospital transfer, for
example, which were not collected in this report are
being captured in this evolving dataset. Although
present registry data support PAC use to manage pa-
tients with CS requiring MCS, definitive randomized
controlled trials are necessary to confirm this
observation.
CONCLUSIONS
This study presents data from one of the largest
multicenter registries representing real-world pa-
tients with CS in the contemporary acute MCS era.
Use of complete hemodynamic data obtained by
timely placement of PACs prior to MCS initiation was
associated with lower mortality in patients with
advanced Stages of CS.
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APPENDIX For supplemental tables, please
see the online version of this paper.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: There is
considerable variability in PAC usage among tertiary care
centers for patients with CS. Complete hemodynamic
profiling of CS patients with PACs prior to MCS initiation
was associated with improved outcomes in a large,
multicenter registry of CS patients supported with mul-
tiple MCS device platforms. This association was
particularly evident in patients with the greatest degree
of hemodynamic compromise.
TRANSLATIONAL OUTLOOK: A randomized,
controlled trial evaluating PAC use in patients with CS
being considered for MCS is necessary because prior trials
have largely excluded patients with CS, and none have
been conducted in the era of widespread MCS use.
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